

Cont
A7

37. (New) A method according to claim 19, a composition being in the form of powder.

REMARKS

The above preliminary amendment is made to remove multiple dependencies from claims 3, 4, 6, 7, 8, 9, 10, 11, 13, 14, 15, 18, 20, 21, 24 and 25.

Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.

If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, John J. Gresens (Reg. No. 33,112), at (612) 371.5265.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Dated: February 26, 2001

By



John J. Gresens
Reg. No. 33,112

JJG/tvm

MARKED-UP COPY

3. (Amended) A formula feed according to claim 1 [or claim 2], in which the concentration of XOR exceeds the normal physiological concentration of XOR.
4. (Amended) A formula feed according to [any one of claims 1 to 3] claim 1, which included up to 500 µg/ml active xanthine oxidoreductase.
6. (Amended) A formula feed according to [any one of claims 1 to 5] claim 1, in which the formulation includes buttermilk, the buttermilk including active XOR.
7. (Amended) A formula feed according to [any one of claims 1 to 6] claim 1, in which the formulation is in liquid form.
8. (Amended) A formula feed according to [any one of claims 1 to 7] claim 1, the formulation further including one or more electron donors.
9. (Amended) A formula feed according to [any one of claims 1 to 8] claim 1, the formulation further including one or more electron acceptors.
10. (Amended) A formula feed according to [any one of claims 1 to 9] claim 1, which is suitable for feeding a human infant.
11. (Amended) A combination product for use in the preparation of a formula feed according to [any one of claims 1 to 10] claim 1, in which the product comprises two separate portions, the first portion including active XOR and the second portion being sterilized and comprising substantially no active XOR.
13. (Amended) A combination product according to claim 11 [or claim 12], in which the second portion has been heat treated.

14. (Amended) A combination product according to [any one of claims 11 to 13] claim 11, in which the first portion has been pasteurized.

15. (Amended) A combination product according to [any one of claims 11 to 14] claim 11, in which the first portion is in a first container, and the second portion is in a second container.

18. (Amended) A composition according to claim 16 [or claim 17], the composition being in the form of a powder.

20. (Amended) A method according to claim 19, [the composition being according to any one of claims 16 to 18] a composition for use in the treatment of gastrointestinal infection, the composition being suitable for addition to a formula feed, and the composition comprising active XOR in combination with one or more electron donors and/or one or more electron acceptors.

21. (Amended) A method according to claim 19 [or claim 20], the method comprising the steps of:

- a. preparing a first portion of the formula feed, comprising a composition including active XOR; and
- b. preparing a second portion of the formula feed, the first portion and second portion being separate from each other for subsequent mixing to form the formula feed.

24. (Amended) A method according to [any one of claims 21 to 23] claim 21, in which the first portion has been subjected to a heat treatment step in which its temperature does not exceed 65°

C.

25. (Amended) A method according to claim 21 [or claim 22], in which the second portion comprises a sterilized feed composition.